Navigation Links
Ten Questions to Ask When Considering COBRA Following a Disability
Date:8/5/2008

his or her former employer's group health plan for a limited time.

"Initially, this may seem like an obvious choice -- yes, of course, you want to continue to have the health coverage you had while employed," Mr. Gada said. "However, there is a cost -- and it can be at a premium."

Ten Questions to Consider With COBRA

To help clarify http://www.allsup.com/Financial-Matters/Managing-Healthcare-Costs.aspx [the healthcare choice] for people with disabilities, Allsup offers the following 10 questions to consider when getting COBRA or continuing COBRA coverage:

1.   Are you eligible? To be eligible, you must have been enrolled in your employer's health plan when you worked and the health plan must continue to be in effect for active employees. If you are eligible for COBRA, you should get a detailed notice with coverage and application details from your former employer's benefits administrator or the group health plan.

2.   Do you have dependents? If your healthcare coverage provides benefits for family members in addition to yourself, then there is an added advantage to continuing this coverage. An alternative may be to consider the healthcare coverage offered through a spouse's employer, if available.

3.   Are you http://www.allsup.com/About-SSDI/Why-You-Want-SSDI.aspx [applying for Social Security disability benefits]? COBRA generally allows you and your dependents to keep the group health plan coverage for 18 months after your employment ends. There is an additional 11-month extension available when a qualified beneficiary is determined by the Social Security Administration (SSA) to be disabled. This would provide 29 months of healthcare coverage.

4. 
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6

Related medicine news :

1. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
2. Study Questions Dead-End Cancer Clinical Trials
3. 6 Years Later, 9/11 Health Questions Linger
4. RFID Implant Cancer Questions Concern Patients
5. Study Questions Genetic Screening for Treatable Diseases
6. New study questions the validity of publishing hospital mortality rates
7. Study Questions Flu Shots Value for Older People
8. Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology
9. Study questions assumptions about human sensitivity to biological motion
10. Childrens Miracle Network Hospital Doctors On Call to Answer Questions About MRSA Infection
11. New study questions disparities in vascular surgery among Hispanics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ten Questions to Ask When Considering COBRA Following a Disability 
Ten Questions to Ask When Considering COBRA Following a Disability
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 2Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 3Health News:Blues CEO Encourages Graduates to Stay and Lead Michigan 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 3Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 4Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 2Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 3Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 4Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8